This technology is a simple and efficient way for synthesizing Singulair, a drug for the treatment of asthma and sesonal allergies.
Features & Benefits
Background of Invention
FDA approved commercial medication for asthma and other allergic symptoms features Singulair. The drug is currently manufactured by a Merck process that requires 10 steps and proceeds in 6.8% overall yield. Researchers at Oregon State University have discovered a very efficient way of synthesizing Singulair. This drug could have powerful implications for treatment of depression and neuropathic pain. Our synthesis requires 4 steps, proceeds in 73.3% overall yield and uses a novel catalyst we designed and developed for the key stepintroduction of the important sulfur constituent into the molecule.